Supportive Care in Cancer最新文献

{"title":"A critical review of randomized controlled trials on topical corticosteroids for the prevention of radiation dermatitis in breast cancer.","authors":"Olivia Kuszaj, Marley Day, Shirley S W Tse, Shing Fung Lee, Alyssa J Wang, Sarah Bayrakdarian, Danny Vesprini, Kimberly Corbin, Irene Karam, J Isabelle Choi, Gustavo N Marta, Jeffrey Q Cao, Tarek Hijal, Rosemary Hill, Francois Gallant, Adrian W Chan, Edward Chow, Henry C Y Wong","doi":"10.1007/s00520-025-09178-2","DOIUrl":"10.1007/s00520-025-09178-2","url":null,"abstract":"<p><strong>Introduction: </strong>Topical steroids have shown effectiveness in preventing radiation dermatitis (RD) in breast cancer patients in randomized controlled trials (RCTs). This review provides an in-depth analysis of the study methodology of these RCTs to review whether topical steroids should be employed in routine clinical practice.</p><p><strong>Methods: </strong>A systematic literature search of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials was conducted from database inception until May 31, 2024. RCTs comparing topical steroids with moisturizers or placebo for the prophylaxis of RD in breast cancer patients were included. The methodology of the RCTs, including how topical steroids were applied, whether crossover in the control arm was allowed, if stratification factors were employed, and the reporting of side effects was evaluated.</p><p><strong>Results: </strong>Twelve RCTs met inclusion criteria. Four different topical steroids were used, including betamethasone 0.1%, mometasone 0.1%, hydrocortisone 1%, and beclomethasone. Eleven studies (92%) showed that topical steroids were effective in reducing incidence or delaying occurrence of grade 2 or above RD with a relative risk of 0.69 (range, 0.19 to 0.98). In all RCTs, topical steroids were consistently used from the start of radiotherapy (RT) until completion to 3 weeks post-RT. Five RCTs (42%) provided patient education on topical steroid application. Six (50%) reported on subsequent management if moist desquamation occurred. Four studies (33%) stratified potential risk factors of RD during randomization. No studies reported any long-term side effects of topical steroids.</p><p><strong>Conclusion: </strong>Topical steroids are effective in reducing the incidence of RD. However, heterogeneity was observed among the RCTs with regard to how and when the topical steroids were applied. The long-term safety profile of topical steroids is not well studied. In the context of modern radiotherapy planning techniques and increased use of hypofractionation radiation schedules, a repeat RCT addressing these methodological concerns may provide more guidance to clinicians.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"147"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews.","authors":"Darren Haywood, Ashley M Henneghan, Alexandre Chan, Raymond J Chan, Haryana M Dhillon, Maryam B Lustberg, Janette L Vardy, Moira O'Connor, Norah Elvidge, Evan Dauer, Oscar Y Franco-Rocha, Shradha Vasan, James Murray, Megan Crichton, Helen Wilding, Susan L Rossell, Nicolas H Hart","doi":"10.1007/s00520-025-09212-3","DOIUrl":"10.1007/s00520-025-09212-3","url":null,"abstract":"<p><strong>Purpose: </strong>A significant number of cancer survivors experience cancer-related cognitive impairment (CRCI), which can impact their ability to think, reason, make decisions, and perform daily actions. In recent years, non-pharmacological interventions for CRCI have gained significant attention. These interventions include exercise, cognitive behavioural therapy, cognitive training/remediation, dietary, mind-body, and multi-modal/complex interventions. This umbrella review provides a critical overview to inform guidelines and current practice, identify the most promising interventions, and uncover gaps in the research literature.</p><p><strong>Methods: </strong>This umbrella review of systematic reviews was pre-registered on Open Science Framework and PROSPERO. Six databases were searched. Systematic reviews (SR) assessing any non-pharmacological interventions to improve cognition in cancer (any type) were included. The overview followed gold-standard guidelines and recommendations. The results were narratively synthesised, and descriptive statistics and effect size ranges were calculated.</p><p><strong>Results: </strong>Sixty-four (n = 64) SRs were included. Results were synthesised into four non-pharmacological domains. Cognitive training/rehabilitation had the strongest evidence for efficacy. Physical activity/exercise showed promising efficacy; however, the variability of findings was considerable. Mind-body and psychological/behavioural therapy interventions were limited, but there was evidence for short-term effectiveness. Multi-modal/complex interventions showed potential for improving cognition in cancer but were poorly defined.</p><p><strong>Conclusions: </strong>Overall, non-pharmacological interventions demonstrated efficacy for improving cognition in cancer. There were limited intervention characteristics within domains which were consistently related to efficacy. Three key recommendations are provided for future research: (1) adopt harmonisation and reporting guidelines; (2) develop definitional guidelines of cognitive domains for CRCI research; and (3) assess intervention and participant characteristics associated with positive versus null/negative findings.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"151"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features, procalcitonin concentration, and bacterial infection in febrile hospitalized cancer patients: a descriptive study and association analysis.","authors":"Pornpimon Patipatdontri, Rattagan Kajeekul, Jirawat Thanestada","doi":"10.1007/s00520-025-09216-z","DOIUrl":"10.1007/s00520-025-09216-z","url":null,"abstract":"<p><strong>Background: </strong>Fever in cancer patients can occur for reasons other than bacterial infections. Without practical tools to distinguish actual infections, treatment delays may occur, reducing effectiveness and increasing antibiotic resistance. This study aimed to identify clinical features and procalcitonin (PCT) levels as indicators of bacterial infection in fevers among cancer patients.</p><p><strong>Methods: </strong>This retrospective study enrolled 225 patients with cancer and fever at the Maharat Nakhon Ratchasima Hospital. Data on the clinical characteristics, laboratory results, and bacterial cultures were collected. Associations were analyzed using logistic regression, and the appropriate PCT cutoff point was determined using ROC analysis.</p><p><strong>Results: </strong>Of 225 cancer patients with fever, 54 (24%) had positive bacterial cultures, with Klebsiella pneumoniae being the most common pathogen. Significant clinical features included age (OR 1.06, 95% CI 1.01-1.12), increased heart rate (OR 1.05, 95% CI 1.02-1.08), and localizing symptoms (OR 7.62, 95% CI 2.49-22.70). Key laboratory findings were absolute neutrophil count (OR 1.15, 95% CI 1.03-1.28) and PCT level (OR 1.39, 95% CI 1.07-1.80). Appropriate PCT cutoff points for predicting bacterial infection were analyzed using various methods, resulting in values of 1.045, 0.546, 0.546, and 0.4025 ng/ml. The concordance probability and closest to the point (0,1) methods suggested a rounded cutoff point of 0.5 ng/ml, which provided a sensitivity of 61% and a specificity of 78%. The AUC for PCT was 0.731, indicating moderate accuracy.</p><p><strong>Conclusion: </strong>Procalcitonin, in conjunction with clinical features, may be used to classify the cause of fever in cancer patients. Therefore, a clinically predictive model would be useful.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"148"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Care for patients with cancer and substance use disorders: a qualitative study of oncology team experiences.","authors":"Sachin S Kale, Laura J Rush, Jennifer L Eramo, Mireille Bitangacha, Sadie Chen, Devon K Check, Katie Fitzgerald Jones, Jessica Merlin, Ann Scheck McAlearney","doi":"10.1007/s00520-025-09181-7","DOIUrl":"10.1007/s00520-025-09181-7","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical decisions surrounding cancer care can be complicated by co-occurring substance use disorders (SUDs), particularly with respect to pain management and cancer treatment safety. Yet, few studies have examined oncology teams' experiences treating patients with co-occurring cancer and SUDs. We therefore sought to understand the perspectives of oncology team providers regarding the challenges they face when caring for patients with cancer and SUDs.</p><p><strong>Methods: </strong>We conducted a qualitative study to understand the experiences of clinicians who have provided cancer care to patients with concurrent SUD. Questions about substances used focused mainly on non-prescribed opioids and stimulants. Individual interviews were conducted in March-July 2023 by telephone or videoconference, recorded, transcribed verbatim, and analyzed rigorously using thematic analysis.</p><p><strong>Results: </strong>Twenty-seven individuals were interviewed (15 physicians, 8 advanced practice providers, 2 registered nurses, and 2 social workers). Specialties included medical oncology, hematology, radiation oncology, and gynecology oncology. We identified four themes representing the challenges oncology teams face when caring for patients with cancer and SUD: (1) patients' unmet social needs; (2) uncertainty about pain management options; (3) implicit biases about patients with SUDs; and( 4) patients' active substance use.</p><p><strong>Conclusion: </strong>Oncology teams face many challenges when caring for patients with cancer and SUDs. Understanding these challenges is critical and can both inform the design of interventions for patients with cancer and SUD and guide future research.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"146"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the impact of the COVID-19 pandemic on cancer-related distress among thoracic oncology patients at a rural cancer center.","authors":"Sierra M Silverwood, Douglas Peters, Veronica Bernacchi, Yelena Kier, Kelly A Hirko","doi":"10.1007/s00520-025-09208-z","DOIUrl":"10.1007/s00520-025-09208-z","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer-related distress (CRD) is frequently observed in rural settings and may have been exacerbated during the COVID-19 pandemic. We examined pre and post COVID-19 changes in CRD among individuals treated for thoracic cancers at a rural cancer center.</p><p><strong>Methods: </strong>Patient demographics, clinical information, and CRD measures derived from the National Comprehensive Cancer Network psychosocial distress problem list were abstracted from electronic medical records for thoracic oncology patients treated at a rural Michigan cancer center before (January 1, 2019-January 1, 2020; n=139) and during (January 20, 2020-January 31, 2021; n=84) the COVID-19 pandemic. CRD scores were calculated by summing the items on the problem lists, and the prevalence of CRD was examined both overall and by specific sources of distress (practical, emotional, social, and physical concerns). We assessed changes in CRD overall and by type using chi-square tests, Fisher's exact tests, and multivariable logistic regression models.</p><p><strong>Results: </strong>CRD prevalence increased by 9.1% during vs. before the pandemic (97.6% vs. 88.5%; p=0.02), with the largest increases evident for emotional (82.1% vs. 64.0%; p=0.004) and physical (82.1% vs. 67.6%; p=0.02) concerns. CRD scores were slightly higher during vs. before the pandemic, but the differences were not significant (all p-values≥0.05). Compared to those treated in the year prior, patients treated during the pandemic had higher odds of elevated CRD (OR (95% CI) =1.86 (1.1, 3.2)), and practical concerns (OR (95% CI) =2.19 (1.3, 3.8)).</p><p><strong>Conclusions: </strong>Findings from this preliminary study suggest an increased prevalence of CRD among rural thoracic oncology patients treated during compared to before the COVID-19 pandemic.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"150"},"PeriodicalIF":2.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.","authors":"Colin Vercueil, Romain Varnier, Romain Seban, Lisa Ciaptacz, Julien Pavillet, Cléa Fraisse, Tiffany Darbas, Safa Abdallahoui, David Cox, Sophie Martin, Philippe Trensz, Jean-Emmanuel Kurtz, Justine Gantzer, Shanti Amé, Carole Bouleuc, Gisèle Chvetzoff, Lauriane Eberst","doi":"10.1007/s00520-025-09202-5","DOIUrl":"10.1007/s00520-025-09202-5","url":null,"abstract":"<p><strong>Purpose: </strong>Therapeutic management of metastatic cancer patients who are hospitalized at the time of initial diagnosis because of impaired performance status and/or severe symptoms is challenging for clinicians. This study aims to describe their outcome.  METHODS: In this prospective multicentric study, we included all adult, inpatients with newly diagnosed metastatic solid tumors between November 2021 and May 2022. Patients were followed for 3 months.. Our primary objective was to describe overall survival (OS). Secondary objectives included assessing SANT effectiveness in specific subgroups, identifying baseline factors associated with SANT initiation, and assessing usual prognostic tools and factors associated with response.</p><p><strong>Results: </strong>107 patients were included. Seventy-four (69%) initiated a SANT. Among them, 39 patients were alive at 3 months. Median overall survival was 1.7 months for the entire cohort. Thirty-seven patients (55%) died in the unit where they were first admitted. Patients with chemo-sensitive tumors, such as testicular non-seminomatous germ cell tumors (100% OS at 3 months), or those receiving targeted therapies or hormone therapies (80% OS at 3 months), showed numerically better outcomes. Factors associated with the initiation of a SANT were young age (OR = 0,94 [0,90; 0,98]), low Charlson Comorbidity Index (OR = 0,56 [0,42; 0,73]), and patient's or caregiver's request for treatment (respectively, OR = 0,07 [0,02; 0,17] and 0,17 [0,06; 0,42], compared to the respective reference category (no request)).</p><p><strong>Conclusion: </strong>Metastatic cancer patients hospitalized at the time of diagnosis share a similar poor survival. Despite the notable exception of chemo-sensitive tumors and specific molecular alterations, the high mortality observed in both groups suggests that SANT has a limited impact on their outcomes. Best supportive care can be reasonably considered for these patients. The benefit of SANT in this altered population should be assessed in larger prospective studies.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"145"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study.","authors":"Sung Hoon Jeong, Seong Min Chun, Hyunji Lee, Miji Kim, Mira Choi, Ja-Ho Leigh","doi":"10.1007/s00520-025-09169-3","DOIUrl":"10.1007/s00520-025-09169-3","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer-related lymphedema (BCRL) is a well-known complication of breast cancer treatment, which often includes chemotherapy. This study aimed to investigate the association between chemotherapy and the risk of developing BCRL in patients with new-onset breast cancer.</p><p><strong>Methods: </strong>This nationwide retrospective cohort study utilized data from the Korean National Health Insurance database and the Korea National Cancer Incidence Database (2006-2017). Using 1:1 propensity score matching, 37,202 participants who received chemotherapy and 37,202 who did not receive chemotherapy were included in the analysis. Cox proportional hazard regression models were employed to examine the association between chemotherapy and the risk of developing BCRL.</p><p><strong>Results: </strong>Among the 74,404 participants, 11,508 (15.5%) were diagnosed with BCRL during the follow-up period. Compared with patients who did not receive chemotherapy, the risk of BCRL was higher in patients undergoing chemotherapy (hazard ratio [95% confidence interval]: 1.95 [1.87-2.04]). Furthermore, compared to patients who did not receive chemotherapy, the risk of BCRL was confirmed in the taxane (3.38 [3.19-3.58]), antimetabolite (1.79 [1.67-1.91]), and anthracycline (1.49 [1.41-1.56]) chemotherapy groups.</p><p><strong>Conclusion: </strong>Chemotherapy administration following a diagnosis of breast cancer increases the risk of BCRL. Therefore, vigilant monitoring for BCRL, particularly in patients undergoing chemotherapy with taxanes, antimetabolites, or anthracyclines, is warranted during follow-up.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"143"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity promotion and participation for people living with and beyond head and neck cancer: A mixed methods study.","authors":"Hannah C Doughty, Kerry Woolfall, Ruaraidh A Hill, Adrian W Midgley, Joanne M Patterson, Lynne M Boddy, Simon N Rogers, Nefyn H Williams","doi":"10.1007/s00520-025-09198-y","DOIUrl":"10.1007/s00520-025-09198-y","url":null,"abstract":"<p><strong>Purpose: </strong>Head and neck cancer (HaNC) can be debilitating, resulting in high symptom burden. Physical activity (PA) can improve quality of life; however, less than 9% of HaNC patients are physically active. This study explored barriers to, and facilitators of, PA promotion and participation for HaNC patients.</p><p><strong>Methods: </strong>Semi-structured interviews with patients, family members and healthcare professionals were conducted. A questionnaire was used to measure patients' self-reported self-efficacy (The General Self-Efficacy Scale) and patients' and healthcare professionals' self-reported PA (The International PA Questionnaire - Short Form). Qualitative data were analysed using reflexive thematic analysis and quantitative data were analysed descriptively. Data were synthesised drawing on the Capability-Opportunity-Motivation-Behaviour model and the Theoretical Domains Framework.</p><p><strong>Results: </strong>Twenty-eight patients, 10 family members and 18 healthcare professionals participated. Most patients self-reported moderate-to-high levels of PA and self-efficacy. Professionals self-reported high levels of PA. Patients were unaware of the benefits of PA for managing side effects and improving quality of life. Family members and professionals were fearful of patients causing themselves harm by being physically active (reflective motivation and beliefs about consequences). Some professionals did not consider it within their role to promote PA to HaNC patients. Many professionals stated they required training in PA promotion, and patients and family members stated they required information and guidance (psychological capability and knowledge).</p><p><strong>Conclusion: </strong>The responsibility of PA promotion is multidisciplinary and educating patients on the benefits and safety of PA may mitigate treatment-related side effects and improve quality of life. Future research should explore if barriers to, and facilitators of, PA behaviour change over a patient's treatment trajectory.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"141"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy.","authors":"Daniel L Hertz, Mary Tanay, Cindy Tofthagen, Emanuela Rossi, Davide Paolo Bernasconi, Katharine E Sheffield, Martha Carlson, Larissa Nekhlyudov, Lisa Grech, Diane Von Ah, Samantha J Mayo, Kathryn J Ruddy, Alexandre Chan, Paola Alberti, Maryam B Lustberg","doi":"10.1007/s00520-025-09190-6","DOIUrl":"10.1007/s00520-025-09190-6","url":null,"abstract":"<p><strong>Purpose: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating toxicity of many drugs used in cancer treatment. There are numerous available strategies for preventing or treating CIPN, but few are guideline-recommended, due to limited evidence of their effectiveness. The primary objective of this survey was to understand what strategies patients used to prevent or treat CIPN, and to understand their perceptions around CIPN prevention and treatment.</p><p><strong>Methods: </strong>The Multinational Association of Supportive Care in Cancer (MASCC) Neurological Complications Study Group created a cross-sectional online survey to recruit individuals who are currently or had previously received neurotoxic chemotherapy treatment and self-reported peripheral neuropathy. Descriptive statistics were reported.</p><p><strong>Results: </strong>Most of the 447 survey participants did not use any CIPN prevention strategy (71%), though given options of any strategy the plurality preferred a prescribed medication or supplement (30%). The most common treatment strategy used was exercise (47%), with some patients trying prescription medications including non-guideline recommended gabapentin (33%) or guideline-recommended duloxetine (8%) options. Nearly half of participants (49%) used at least one non-prescribed medication for treating CIPN. Patients often followed suggestions of their medical oncology clinical team, but sometimes relied on the internet or other patients to recommend non-prescription strategies.</p><p><strong>Conclusion: </strong>In the absence of many guideline-recommended strategies for CIPN prevention and treatment, some patients use options with minimal evidence of effectiveness. Additional research is needed to determine which strategies are effective for prevention and treatment so these can be implemented in practice to improve treatment outcomes in patients with cancer.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"142"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of deep diaphragmatic breathing on fatigue in patients with metastatic gastrointestinal cancers: a randomized clinical trial.","authors":"Maryam Rezaei, Alireza Abdi, Nader Salari, Mozaffar Aznab, Seyed Vahid Jasemi","doi":"10.1007/s00520-025-09207-0","DOIUrl":"10.1007/s00520-025-09207-0","url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a common and unpleasant symptom experienced by many cancer patients. One method that has been suggested to reduce fatigue is deep diaphragmatic breathing. However, there is limited information available regarding the effectiveness of this technique for patients with advanced cancers. As a result, this study was conducted to investigate the impact of deep diaphragmatic breathing on fatigue in patients with gastrointestinal tract cancers that have spread to other parts of the body.</p><p><strong>Methods: </strong>This study, conducted in the oncology departments of Imam Reza (AS) Kermanshah Hospital in 2022, aimed to investigate the effects of an intervention test on 44 patients with malignant gastrointestinal cancer. Inclusion criteria include metastatic cancer of the gastrointestinal tract, the patient's consent to cooperate, and the age of 18-65 years. Exit criteria also include transfer from the oncology department, death, misdiagnosis, and non-cooperation The patients were selected as available and randomly assigned to two groups: an experimental group and a control group. The intervention test was performed by the experimental group twice a day for 10 days, with each session lasting for 10 min. Before and after the intervention, both groups completed research tools, which included Piper's fatigue questionnaire and a demographic information checklist. The data collected was analyzed using SPSS version 25 software.</p><p><strong>Findings: </strong>According to the findings, before the intervention, the average total fatigue was measured at 5.15 ± 1.98 in the case group and 4.43 ± 1.74 in the control group, with no significant difference between the two groups (p = 0.213). However, after the intervention, the average total fatigue decreased to 3.59 ± 1.91 in the case group, whereas it increased to 6.14 ± 1.91 in the control group, with a significant difference between the two groups (p = 0.001).</p><p><strong>Conclusion: </strong>The study revealed that the method used in the treatment had a significant impact on reducing fatigue in patients. Considering its low cost and high feasibility, it is recommended to include this approach in the care plan for patients and make it a part of their routine.</p><p><strong>Trial registration: </strong>IRCT20220104053628N1, date: 2022-02-05.</p>","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 2","pages":"144"},"PeriodicalIF":2.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}